Aliases & Classifications for Mucinoses

MalaCards integrated aliases for Mucinoses:

Name: Mucinoses 12 41 14 69

External Ids:

Disease Ontology 12 DOID:3141
MeSH 41 D017520
SNOMED-CT 64 11528001
UMLS 69 C0162855

Summaries for Mucinoses

MalaCards based summary : Mucinoses is related to spinal cord astrocytoma and hand, foot and mouth disease. An important gene associated with Mucinoses is CHST11 (Carbohydrate Sulfotransferase 11), and among its related pathways/superpathways are Allograft rejection and Interferon gamma signaling. The drugs Polidocanol and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and bone marrow, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Related Diseases for Mucinoses

Graphical network of the top 20 diseases related to Mucinoses:



Diseases related to Mucinoses

Symptoms & Phenotypes for Mucinoses

MGI Mouse Phenotypes related to Mucinoses:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.91 INS CHST11 KRT14 FBN1 IFNB1 IFNG
2 endocrine/exocrine gland MP:0005379 9.88 CD44 INS CHST11 KRT14 FBN1 IFNG
3 immune system MP:0005387 9.87 CD44 INS CHST11 KRT14 FBN1 IFNB1
4 digestive/alimentary MP:0005381 9.83 IFNG CD44 INS CHST11 KRT14
5 muscle MP:0005369 9.65 IFNG CD44 INS CHST11 FBN1
6 renal/urinary system MP:0005367 9.55 INS CHST11 FBN1 IFNG CD44
7 respiratory system MP:0005388 9.35 IFNG CD44 CHST11 KRT14 FBN1
8 skeleton MP:0005390 9.1 CD44 INS CHST11 FBN1 IFNB1 IFNG

Drugs & Therapeutics for Mucinoses

Drugs for Mucinoses (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Polidocanol Approved Phase 4 9002-92-0
2
Ranibizumab Approved Phase 4 347396-82-1 459903
3
Ropivacaine Approved Phase 4,Phase 3 84057-95-4 175805 71273
4
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
5
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
7
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
8
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2 76-42-6 5284603
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
10
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
11
Nicotinamide Approved, Investigational, Nutraceutical Phase 4 98-92-0 936
12 Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 2
13
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-02-9 14985
14 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
15 Angiogenesis Inhibitors Phase 4
16 Angiogenesis Modulating Agents Phase 4
17 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
18 Anesthetics, Local Phase 4,Phase 3,Phase 2,Phase 1
19 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Antiemetics Phase 4
22 Antimetabolites Phase 4,Phase 1,Phase 2
23 Antioxidants Phase 4
24 Autonomic Agents Phase 4
25 Gastrointestinal Agents Phase 4
26 Hypolipidemic Agents Phase 4
27 Lipid Regulating Agents Phase 4
28 Micronutrients Phase 4
29 Nicotinic Acids Phase 4
30 Protective Agents Phase 4,Phase 1,Phase 2
31 Tocopherols Phase 4,Phase 2
32 Tocotrienols Phase 4,Phase 2
33 Trace Elements Phase 4
34 Vasodilator Agents Phase 4
35 Vitamin B Complex Phase 4
36 Vitamins Phase 4,Phase 2
37 Antibodies Phase 4,Phase 1,Phase 2
38 Immunoglobulins Phase 4,Phase 1,Phase 2
39 Analgesics Phase 4,Phase 2
40 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
41 Antirheumatic Agents Phase 4,Phase 1,Phase 2
42 Acetaminophen, hydrocodone drug combination Phase 4
43 Analgesics, Non-Narcotic Phase 4,Phase 2
44 Analgesics, Opioid Phase 4,Phase 2
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
46 Antipyretics Phase 4,Phase 2
47 Antitussive Agents Phase 4
48 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
49 Cyclooxygenase Inhibitors Phase 4,Phase 2
50 Narcotics Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 186)

# Name Status NCT ID Phase Drugs
1 An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cyst Unknown status NCT02154789 Phase 4 polidocanol
2 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4 Ranibizumab
3 Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation Completed NCT02651519 Phase 4 0.25% ropivacaine hydrochloride;saline
4 Effect of Stellate Ganglion Block on Meniere's Disease Completed NCT01574313 Phase 4 0.25mg, fludiazine;25mg cephadol@ (diphenidol);200mg kentons@ (tocopherol nicotinate).
5 Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy Completed NCT00607386 Phase 4
6 A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI Completed NCT00299000 Phase 4 Naglazyme
7 A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease Completed NCT00144781 Phase 4
8 A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients Completed NCT00144768 Phase 4 laronidase
9 Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age Recruiting NCT02455622 Phase 4 Elaprase for intravenous (IV) infusion
10 A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants Recruiting NCT00418821 Phase 4
11 Post-operative Analgesia in Elective, Soft-tissue Hand Surgery Enrolling by invitation NCT02029235 Phase 4 Acetaminophen/Hydrocodone;Acetaminophen/Ibuprofen
12 Morquio's Syndrome: a Case Study Terminated NCT00609440 Phase 4
13 BMN 110 Phase 3B in Australian Patients Unknown status NCT01966029 Phase 3 BMN 110
14 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
15 Surgery Versus Manual Rupture for Dorsal Carpal Ganglion Completed NCT01017900 Phase 3
16 A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) Completed NCT02230566 Phase 3 UX003
17 Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment Completed NCT02055118 Phase 2, Phase 3
18 A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01275066 Phase 3 BMN 110 Weekly;Placebo;BMN 110 Every Other Week
19 Safety and Efficacy of Hunterase Completed NCT01645189 Phase 3
20 Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01415427 Phase 3 BMN 110 - Weekly;BMN 110 - Every Other Week
21 Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I Completed NCT00912925 Phase 3
22 Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase Completed NCT00630747 Phase 2, Phase 3
23 Study of rhASB in Patients With Mucopolysaccharidosis VI Completed NCT00104234 Phase 3 N-acetylgalactosamine 4-sulfatase;Placebo/rhASB
24 Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II) Completed NCT00069641 Phase 2, Phase 3
25 Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI Completed NCT00067470 Phase 3 Placebo;N-acetylgalactosamine 4-sulfatase
26 Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease Completed NCT00258011 Phase 3
27 Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients Completed NCT00146770 Phase 3
28 Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain Recruiting NCT02821169 Phase 3 ropivacaine;saline solution 0.9%
29 A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7 Active, not recruiting NCT02432144 Phase 3 UX003
30 Long-Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094 Enrolling by invitation NCT02412787 Phase 2, Phase 3 Idursulfase-IT
31 ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Terminated NCT00654433 Phase 3
32 Clinical Trial of Growth Hormone in MPS I, II, and VI Terminated NCT00748969 Phase 2, Phase 3 Somatropin (DNA origin)
33 The Efficacy of Stellate Ganglion Block as Post-traumatic Stress Disorder (PTSD) Therapy: A Pilot Study Unknown status NCT01533610 Phase 2
34 Analgesic Effect of an Injection of Botulinum Toxin Type A in the Ganglion Impar in Patients With Chronic Proctalgia Completed NCT01331356 Phase 2 Botox
35 A Study of JR-141 in Patients With Mucopolysaccharidosis Type II Completed NCT03128593 Phase 1, Phase 2 JR-141
36 Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI Completed NCT02437253 Phase 1, Phase 2 Adalimumab
37 Long-term Follow-up of Sanfilippo Type A Patients Treated by Intracerebral SAF-301 Gene Therapy Completed NCT02053064 Phase 1, Phase 2
38 An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) Completed NCT01856218 Phase 1, Phase 2 UX003
39 Intracerebral Gene Therapy for Sanfilippo Type A Syndrome Completed NCT01474343 Phase 1, Phase 2
40 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease Completed NCT02060526 Phase 2 Recombinant human heparan N-sulfatase [rhHNS]
41 To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients Completed NCT01301898 Phase 1, Phase 2 GC1111_0.5mg/kg;GC1111_1.0mg/kg;Elaprase_0.5mg/kg
42 Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01515956 Phase 2 BMN 110
43 A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA Completed NCT00884949 Phase 1, Phase 2 BMN 110
44 Immune Tolerance Study With Aldurazyme® (Laronidase) Completed NCT00741338 Phase 1, Phase 2 Cyclosporine A (CsA);Azathioprine (Aza)
45 Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Completed NCT01043640 Phase 2 Campath-1H;Cyclophosphamide;Busulfan;Cyclosporine A;Mycophenolate Mofetil
46 Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients Completed NCT01155778 Phase 1, Phase 2
47 A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® Completed NCT00920647 Phase 1, Phase 2 Idursulfase IT (1 mg);Idursulfase IT (10 mg);Idursulfase IT (30 mg)
48 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
49 Stem Cell Transplantation for Hurler Completed NCT00176917 Phase 2 Busulfan, Cyclophosphamide, ATG
50 HSCT for High Risk Inherited Inborn Errors Completed NCT00383448 Phase 2 Clofarabine;Melphalan;Alemtuzumab;mycophenylate mofetil;Hydroxyurea

Search NIH Clinical Center for Mucinoses

Cochrane evidence based reviews: mucinoses

Genetic Tests for Mucinoses

Anatomical Context for Mucinoses

MalaCards organs/tissues related to Mucinoses:

38
Eye, Bone, Bone Marrow, Brain, Trigeminal Ganglion, Dorsal Root Ganglion, Spinal Cord

Publications for Mucinoses

Articles related to Mucinoses:

(show all 16)
# Title Authors Year
1
Trauma-induced Focal Nodular Mucinoses: A Rare Entity. ( 29441300 )
2018
2
Review of Primary Cutaneous Mucinoses in Nonlupus Connective Tissue Diseases. ( 28673091 )
2017
3
Diffuse cutaneous mucinoses. ( 12170882 )
2002
4
Cutaneous mucinoses complicating interferon beta-1b therapy. ( 11844903 )
2002
5
Cutaneous mucinoses: microscopic criteria for diagnosis. ( 11391115 )
2001
6
Cutaneous mucinoses and HIV infection. ( 9990377 )
1998
7
The dermal mucinoses. ( 7694631 )
1993
8
Cutaneous toxic mucinoses. ( 1583189 )
1992
9
The new cutaneous mucinoses: a review with an up-to-date classification of cutaneous mucinoses. ( 2007673 )
1991
10
The cutaneous mucinoses. ( 2419372 )
1986
11
Focal mucinosis in dogs: seven cases and review of cutaneous mucinoses of man and animals. ( 3962080 )
1986
12
The acquired cutaneous mucinoses. ( 6486981 )
1984
13
Multiple cutaneous focal mucinoses with hypothyroidism. ( 7053704 )
1982
14
Reticular erythematous mucinosis (REM syndrome) of Steigleder: its relationship to other mucinoses and to chronic erythemata. ( 747554 )
1978
15
The cutaneous mucinoses. ( 4196237 )
1973
16
Histochemical study of acid mucopolysaccharides in mucinoses. ( 13986611 )
1962

Variations for Mucinoses

Expression for Mucinoses

Search GEO for disease gene expression data for Mucinoses.

Pathways for Mucinoses

GO Terms for Mucinoses

Cellular components related to Mucinoses according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 C4A CXCL9 FBN1 IFNB1 IFNG INS
2 endoplasmic reticulum lumen GO:0005788 9.33 C4A FBN1 INS
3 extracellular space GO:0005615 9.17 C4A CXCL9 FBN1 IFNB1 IFNG INS

Biological processes related to Mucinoses according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.43 C4A FBN1 INS
2 humoral immune response GO:0006959 9.37 IFNB1 IFNG
3 defense response to virus GO:0051607 9.33 CXCL9 IFNB1 IFNG
4 positive regulation of nitric oxide biosynthetic process GO:0045429 9.32 IFNG INS
5 regulation of receptor activity GO:0010469 9.02 CXCL9 FBN1 IFNB1 IFNG INS
6 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 8.96 IFNB1 IFNG

Molecular functions related to Mucinoses according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 CXCL9 IFNB1 IFNG

Sources for Mucinoses

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....